Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00345969
Other study ID # HSC 02-1108
Secondary ID
Status Completed
Phase Phase 3
First received June 27, 2006
Last updated January 22, 2018
Start date November 2004
Est. completion date August 2009

Study information

Verified date January 2018
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to determine, in hypogonadal older men with physical frailty, whether exercise training combined with testosterone replacement therapy can improve skeletal muscle strength, and lean mass, to a greater degree than exercise training alone.


Description:

Decreases in physical abilities, including losses of strength, endurance, balance, and coordination are major causes of disability and loss of independence in older men. Such individuals are at high risk for injurious falls, hospitalization, and use of supportive services. Age-associated testosterone deficiency may contribute to deficits in muscle mass and strength that are common in this patient population.

The primary aim of this study is to determine, in hypogonadal older men with physical frailty, whether six months of exercise training combined with testosterone replacement therapy can improve skeletal muscle mass and skeletal muscle strength, to a greater degree than six months of exercise training alone.

Secondary study aims are to determine in hypogonadal older men with physical frailty, whether six months of exercise training combined with testosterone replacement therapy can improve physical function, bone mineral density, and quality of life, to a greater degree than six months of exercise training alone.

Comparison: Men age 65 years and older who meet criteria for physical frailty and have a serum testosterone level below 350 ng/dl are randomly assigned to one of two groups: 1) transdermal testosterone replacement therapy + supervised exercise training for six months vs. 2) inactive placebo gel + supervised exercise training for six months.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date August 2009
Est. primary completion date February 2009
Accepts healthy volunteers No
Gender Male
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Male, age 65 years and older

- Total serum testosterone level < 350 ng/dl

- Total Modified Physical Performance Test Score <28

Exclusion Criteria:

- Inability to walk 50 feet independently

- Current use of estrogen, progestin, or androgen containing compound

- Diagnosis of dementia of severity sufficient to interfere with informed consent or compliance with the protocol, or a score of 11 or greater on the Short Blessed Test of Orientation, Memory and Concentration

- Visual or hearing impairments that interfere with following directions

- Cardiopulmonary disease (recent MI, unstable angina or CHF, etc.), neuromuscular impairments, or unstable medical condition that would contraindicate progressive resistance exercise training

- History of prostate cancer or hormone dependent neoplasia

- PSA level > 4 ng/ml

- Serum liver transaminase levels of greater than 2 standard deviations above normal

- Use of drugs for osteoporosis for less than 1 year

- Current participation in a vigorous exercise or weight-training program more than once per week

- History of sleep apnea requiring use of CPAP

- Uncontrolled thyroid disease

- Diagnosis of cancer within the past 5 years other than superficial skin cancer (squamous or basal cell)

- hematocrit > 50%

- AUA symptom score > 16.

- History of alcohol or substance abuse

- Presence of severe facial acne

- Active symptoms of depression with GDS score > 5 and symptoms severe enough to cause >5% weight loss in previous 3 months or interfere with research assessments

Study Design


Intervention

Drug:
Transdermal Testosterone gel (1%)
Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
Behavioral:
Supervised exercise training
Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine Solvay Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Serum Prostate Specific Antigen (PSA) Level Baseline and Six Months
Other Change in Hematocrit Percentage of the volume of whole blood composed of Red Blood Cells Baseline and Six Months
Other Change in Serum Total Cholesterol Level Baseline and Six Months
Other Change in Serum HDL Cholesterol Level Baseline and Six Months
Other Change in Serum LDL Cholesterol Level Baseline and Six Months
Primary Mean Change in Total Lean Body Mass Total Lean Mass measured by Dual X-ray Absorptiometry (DXA) Baseline and Six Months
Primary Change in Skeletal Muscle Strength by 1-RM One-repetition maximum strength for leg extension Baseline and Six Months
Secondary Change in Isokinetic Leg Extension Torque at 0 Deg/Sec Leg Extension Torque measured with Cybex dynamometer at 0 deg/sec Baseline and Six Months
Secondary Change in Leg Extension Torque at 60 Deg/Sec Leg Extension Torque measured with Cybex dynamometry at 60 deg/sec Baseline and Six Months
Secondary Change in Total Body Fat Mass Total Body Fat Mass as measured by DXA Baseline and Six Months
Secondary Change in Femoral Bone Mineral Density (BMD) Femoral Bone Mineral Density measured with Dual X-ray Absorptiometry (DXA) Baseline and Six Months
Secondary Change in Total Modified Physical Performance (mPPT) Score The Modified Physical Performance Test (mPPT) is a direct observational test that assesses multiple dimensions of physical function (basic and complex activities of daily living [ADL]) with different levels of difficulty. The test consists of 9 performance tasks. The total score range is 0-36 (min-max), with higher scores indicating better performance. Sub-scores are assigned for each of 9 item tasks; sub-score range is 0-4 (min-max) with higher scores indicating better performance. The sub-scores are summed to compute the total score. Baseline and Six Months
Secondary Change in Serum Testosterone Level Total Serum Testosterone Level (ng/mL) Baseline and Six Months
See also
  Status Clinical Trial Phase
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Terminated NCT02419105 - Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors Phase 3
Withdrawn NCT02137265 - Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism N/A
Completed NCT02222558 - Oral Testosterone for the Treatment of Hypogonadism in Males Phase 2
Completed NCT02233751 - Pharmacokinetic Study of Subcutaneous Testosterone Enanthate Phase 1
Completed NCT01887418 - Pharmacokinetic Study of Testosterone Enanthate Phase 1/Phase 2
Terminated NCT01092858 - NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH) Phase 4
Completed NCT00624624 - Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism N/A
Completed NCT00752869 - Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Phase 4
Completed NCT00613288 - Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism N/A
Completed NCT00838838 - Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis N/A
Completed NCT00119483 - Older Men and Testosterone N/A
Completed NCT00004438 - Leuprolide in Treating Adults With Hypogonadotropism N/A
Withdrawn NCT00398034 - Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study. Phase 2
Completed NCT02921386 - The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate Phase 2
Completed NCT02937740 - Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natestoâ„¢ Phase 4
Completed NCT01717768 - Oral Testosterone for the Treatment of Hypogonadism Phase 2
Terminated NCT01460654 - Testosterone and Alendronate in Hypogonadal Men Phase 2
Completed NCT00998933 - Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure Phase 1
Withdrawn NCT00710827 - Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks Phase 4